Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Seager

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal of Personalized Medicine|May 25, 2024
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast CancerRobert J Seager, Heidi Ko, Sarabjot Pabla, et al.
Journal of Translational Medicine|February 7, 2024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancerR J Seager, Maria-Fernanda Senosain, Erik Van Roey, et al.
Breast Cancer (Dove Medical Press)|August 28, 2024
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast CancerHeidi Chwan Ko, R J Seager, Sarabjot Pabla, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal of Personalized Medicine|May 25, 2024
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast CancerRobert J Seager, Heidi Ko, Sarabjot Pabla, et al.
Journal of Translational Medicine|February 7, 2024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancerR J Seager, Maria-Fernanda Senosain, Erik Van Roey, et al.
Breast Cancer (Dove Medical Press)|August 28, 2024
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast CancerHeidi Chwan Ko, R J Seager, Sarabjot Pabla, et al.
Pageof 7